Body weight is the most available number in health and the least informative per kilogram: it cannot tell lost fat from lost muscle, water or bone mineral — tissues with very different consequences. Dieting always had th
Same hormone family, different receptors, different labels: what semaglutide, tirzepatide and investigational retatrutide share, and what the trials can and cannot prove.
What follows is a living summary of retatrutide's trial record, not a forecast of approval or availability. Retatrutide (LY3437943) is Eli Lilly's investigational once-weekly GIP/GLP-1/glucagon "triple agonist"; it is no
One molecule, three hormone receptors — and unusually deep published evidence for an unapproved drug. What retatrutide's trials actually measured, what they do not resolve, and why nothing sold online is the medicine the trials tested.